Fujioka T, Aoki H, Yoshida M, Ohhori T, Kubo T
Department of Urology and Microbiology, Iwate Medical University School of Medicine, Morioka, Japan.
Urol Int. 1989;44(4):198-204. doi: 10.1159/000281504.
The cross-antigenicity between streptococcus, Su strain (OK-432), and rat bladder cancer BC-47 was studied by the immunocytochemistry. Both anti-Su (OK-432) and anti-BC-47 reacted with both homo- and heterogenous antigens. The specificity of the PAP reactions using these sera was confirmed by absorption study of the first antibodies. But, OK-432 did not share with normal rat tissues. Furthermore, the presence of common antigens between OK-432 and animal tumors where OK-432 was effective was indicated by the PAP studies, but OK-432 did not share with tumors where OK-432 was ineffective. By the PAP studies using antigroup A streptococcus-specific C-polysaccharide and antigroup-specific sera, it was suggested that the determinant of the cross-antigenicity was group A-specific C-polysaccharide. The common antigens between OK-432 and human urogenital cancers were also identified by the PAP study. Then, local immunotherapy with OK-432 was carried out in 38 patients with superficial bladder tumor and the tumors were eliminated in 23.7%. In 77.8% of the complete response and in 10.3% of the no change, the tumor tissues demonstrated antigens common between OK-432 and tissues. From these results, it was concluded that common antigens which OK-432 shared with tumors could favorably augment host defense against human bladder tumors, the same as animal tumors.
采用免疫细胞化学方法研究了链球菌Su株（OK - 432）与大鼠膀胱癌BC - 47之间的交叉抗原性。抗Su（OK - 432）和抗BC - 47均与同源和异源抗原发生反应。通过对一抗的吸收研究证实了使用这些血清的PAP反应的特异性。但是，OK - 432与正常大鼠组织无共同抗原。此外，PAP研究表明OK - 432与OK - 432有效的动物肿瘤之间存在共同抗原，但OK - 432与OK - 432无效的肿瘤无共同抗原。通过使用抗A组链球菌特异性C多糖和抗组特异性血清的PAP研究，提示交叉抗原性的决定簇是A组特异性C多糖。PAP研究还鉴定出OK - 432与人泌尿生殖系统癌症之间的共同抗原。然后，对38例浅表性膀胱肿瘤患者进行了OK - 432局部免疫治疗，23.7%的患者肿瘤消退。在完全缓解的患者中，77.8%以及病情无变化的患者中，10.3%的肿瘤组织显示出OK - 432与组织之间的共同抗原。从这些结果得出结论，OK - 432与肿瘤共有的共同抗原能够像在动物肿瘤中一样，有利地增强宿主对人膀胱肿瘤的防御能力。
